Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680836 | 0.73 | DYRK1A (0.62) | GRM4TRPA1DYRK1AKDM4ERAB9A | |
| SCHEMBL25468794 | 0.72 | GRM4 (0.39) | GRM4TRPA1DYRK1AKDM4ERAB9A | |
| SCHEMBL20901588 | 0.72 | GRM4 (0.50) | GRM4TRPA1KCNQ3KCNQ2KCNQ1 | |
| SCHEMBL24198036 | 0.72 | GRM4 (0.34) | GRM4 | |
| SCHEMBL15935281 | 0.71 | GRM4 (0.37) | GRM4 | |
| SCHEMBL10219959 | 0.70 | MAP2K4 (0.51) | — | |
| SCHEMBL29324202 | 0.70 | SGK1 (0.33) | GRM4 | |
| SCHEMBL26424498 | 0.70 | GRM4 (0.30) | GRM4 | |
| SCHEMBL24198307 | 0.69 | TDO2 (0.34) | — | |
| SCHEMBL22901869 | 0.69 | ALDH1A1 (0.37) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | GRM4 4856/4885TRPA1 1375/4885DYRK1A 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.